• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Raymond James Financial Declares Quarterly Dividends on Common and Preferred Stock

    5/20/24 5:54:08 PM ET
    $RJF
    Investment Bankers/Brokers/Service
    Finance
    Get the next $RJF alert in real time by email

    ST. PETERSBURG, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- On May 20, 2024, the Raymond James Financial, Inc. (NYSE:RJF) Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.45 per share, payable July 15, 2024 to shareholders of record on July 1, 2024.

    The Board declared a quarterly dividend of $0.3984375 per depositary share of 6.375% Fixed-to-Floating Rate Series B Non-Cumulative Perpetual Preferred Stock (NYSE:  RJF PrB) payable July 1, 2024, to shareholders of record on June 14, 2024. 

    About Raymond James Financial, Inc.

    Raymond James Financial, Inc. (NYSE:RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. The company has approximately 8,800 financial advisors. Total client assets are $1.45 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.

    Forward-Looking Statements

    Certain statements made in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning future shareholder distributions. Forward-looking statements are not guarantees, and they involve risks, uncertainties and assumptions. Although we make such statements based on assumptions that we believe to be reasonable, there can be no assurance that actual results will not differ materially from those expressed in the forward-looking statements. We caution investors not to rely unduly on any forward-looking statements and urge you to carefully consider the risks described in our filings with the Securities and Exchange Commission (the "SEC") from time to time, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are available at www.raymondjames.com and the SEC's website at www.sec.gov. We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events, or otherwise.



    Media Contact: Steve Hollister
    Raymond James
    727.567.2824
    
    Investor Contact: Kristina Waugh
    Raymond James
    727.567.7654
    
    Get the next $RJF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RJF

    DatePrice TargetRatingAnalyst
    4/30/2025$159.00Buy → Neutral
    BofA Securities
    1/7/2025$151.00 → $166.00Overweight → Neutral
    Analyst
    1/6/2025$161.00 → $185.00Neutral → Buy
    Goldman
    12/12/2024$152.00 → $169.00Overweight → Equal Weight
    Wells Fargo
    10/9/2024$146.00Mkt Perform → Mkt Outperform
    JMP Securities
    9/12/2024$138.00Overweight
    Wells Fargo
    7/8/2024Outperform → Peer Perform
    Wolfe Research
    1/10/2024$110.00 → $135.00Neutral → Overweight
    JP Morgan
    More analyst ratings